Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Severe Acute Respiratory Syndrome (SARS) - Overview
Severe Acute Respiratory Syndrome (SARS) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Severe Acute Respiratory Syndrome (SARS) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Severe Acute Respiratory Syndrome (SARS) - Companies Involved in Therapeutics Development
Severe Acute Respiratory Syndrome (SARS) - Drug Profiles
Severe Acute Respiratory Syndrome (SARS) - Dormant Projects
Severe Acute Respiratory Syndrome (SARS) - Product Development Milestones
Featured News & Press Releases
Apr 05, 2022: VBI Vaccines provides new data on VBI-2901
Mar 31, 2022: Adagio’s antibody meets primary endpoints in Phase II/III Covid-19 trials
Mar 17, 2022: BioVaxys announces bioproduction of BVX-1021 for its pan-sarbecovirus program in collaboration with The Ohio State University
Mar 01, 2022: Study finds MK-4482 inhibits replication of multiple SARS-CoV-2 variants of concern in Syrian hamster COVID-19 model
Dec 22, 2021: Cocrystal Pharma’s COVID-19 oral and intrasal/pulmory protease inhibitors exhibit powerful in vitro potency against the SARS-CoV-2 Omicron variant
Dec 16, 2021: Merck and Ridgeback announce publication of phase 3 study of Molnupiravir, an investigatiol oral antiviral COVID-19 treatment, in the New England Jourl of Medicine
Oct 04, 2021: Merck-Ridgeback’s oral drug lowers hospitalisation risk in Covid-19 trial
Sep 30, 2021: Adagio’s ADG20 demonstrates benefit in Covid-19 clinical programme
Sep 24, 2021: A new oral antiviral drug for COVID is being tested in humans
Jul 26, 2021: Announcement of the effect of OBP-2011 against Indian and South African variants of SARS-CoV-2 virus
Jul 19, 2021: Announcement of manufacturing partnership on OBP-2011, an investigatiol product for COVID-19
Jun 21, 2021: Starpharma provides update on VIRALEZE UK
Jun 14, 2021: Announcement of the effect of OBP-2011 against SARS and MERS
Jun 01, 2021: Scripps Research Institute testing shows Viraleze highly active against UK COVID strain
Apr 19, 2021: NIH study finds antiviral drug effective against Covid-19
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Adagio Therapeutics Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by AIkido Pharma Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by AlphaVax Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Amide Technologies Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Autoimmune Technologies LLC, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Biotron Ltd, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by BioVaxys Technology Corp, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Calder Biosciences Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Cidara Therapeutics Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Citospin SL, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Cloud Pharmaceuticals Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Cocrystal Pharma Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by ConserV Bioscience Ltd, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by CSL Ltd, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Fab’entech SA, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Global BioLife Inc Ltd, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Halo Therapeutics Ltd, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Hinge Bio Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Immodulon Therapeutics Ltd, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Immune Biosolutions Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Lattice Biologics Ltd, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Merck & Co Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Merck KGaA, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Novavax Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Oncolys BioPharma Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Oncovir Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Phelix Therapeutics LLC, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Pulmotect Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Sagimet Biosciences Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Sorrento Therapeutics Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Starpharma Holdings Ltd, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Theravectys SA, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Trimunocor Ltd, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Valo Therapeutics Oy, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by VBI Vaccines Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Dormant Projects, 2022
Severe Acute Respiratory Syndrome (SARS) - Dormant Projects, 2022 (Contd..1)